Several studies are currently conducted to investigate the efficacy and safety of low-dose IL-2 therapy in various other autoimmune diseases such as Crohn’s disease (NCT04263831), Behcet’s disease (NCT04065672), macrophage activation syndrome (NCT02569463), relapsing polychondritis (NCT04077736) or multiple sclerosis (NCT02424396). This evidence concerns the gene IL2 and Crohn disease.